DiaMedica Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 9.52 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 513.37M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment...